Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI

Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said